Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health

作者：Robert A. Kloner, Arthur L. Burnett, Martin Miner, Michael J. Blaha, Peter Ganz, Irwin Goldstein, Noel N. Kim, Tobias Köhler, Tom F. Lue, Kevin T. McVary, John P. Mulhall, Sharon J. Parish, Hossein Sadeghi‐Nejad, Richard Sadovsky, Ira D. Sharlip, Raymond C. Rosen · 发表于：The Journal of Sexual Medicine · 年份：2023 · DOI：10.1093/jsxmed/qdad163 · 被引用次数：54 · 研究领域：Phosphodiesterase function and regulation、Sexual function and dysfunction studies、Pharmaceutical Quality and Counterfeiting

BACKGROUND: In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED who also had cardiovascular disease. These issues were readdressed in the second and third conferences. In the 13 years since the last Princeton Consensus Conference, the experience with PDE5 inhibitors is more robust, and recent new data have emerged regarding not only safety and drug-drug interactions, but also a potential cardioprotective effect of these drugs. AIM: In March 2023, an interdisciplinary group of scientists and practitioners met for the fourth Princeton Consensus Guidelines at the Huntington Medical Research Institutes in Pasadena, California, to readdress the cardiovascular workup of men presenting with ED as well as the approach to treatment of ED in men with known cardiovascular disease. METHOD: A series of lectures from experts in the field followed by Delphi-type discussions were developed to reach consensus. OUTCOMES: Consensus was reached regarding a number of issues related to erectile dysfunction and the interaction with cardiovascular health and phosphodiesterase-5 inhibitors. RESULTS: An algorithm based on recent recommendations of the American College of Cardiology and American Heart Association, including the use of computed tomography coronary artery calcium scoring, was integrated into the eval...